SEC Form 4 · accession 0001209191-16-152916

VERTEX PHARMACEUTICALS INC / MA · VRTX

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director

Period of report

Nov 30, 2016

Accepted (ET)

Dec 2, 2016 · 2:22 pm EST

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0000875320

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock	Nov 30, 2016	M	6,500	$36.30	A	274,725	D
Common Stock^F2,F3	Nov 30, 2016	S	2,200	$82.20	D	272,525	D
Common Stock^F2,F4	Nov 30, 2016	S	2,100	$83.48	D	270,425	D
Common Stock^F2,F5	Nov 30, 2016	S	1,700	$84.53	D	268,725	D
Common Stock^F2,F6	Nov 30, 2016	S	500	$85.53	D	268,225	D
Common Stock	holding	—	—		—	13,286	I	401k
Common Stock	holding	—	—		—	78,200	I	Common Stock Held In Trust

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to Buy)^F7	$36.30	Nov 30, 2016	M	6,500	D	—	Jan 23, 2017	Common Stock	6,500	40,500	D

F1Transaction made pursuant to Dr. Boger's company approved trading plan under Rule 10b5-1.
F2Dr. Boger undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3Open market sales reported on this line occurred at a weighted average price of $82.20 (range $81.90 to $82.74).
F4Open market sales reported on this line occurred at a weighted average price of $83.48 (range $82.97 to $83.80).
F5Open market sales reported on this line occurred at a weighted average price of $84.53 (range $84.14 to $85.00).
F6Open market sales reported on this line occurred at a weighted average price of $85.53 (range $85.35 to $85.85).
F7Fully vested.